Sotorasib for Solid Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a medication called sotorasib. It is aimed at adults who have advanced solid tumors with a specific genetic mutation known as KRAS p.G12C. Sotorasib works by blocking this mutation, which can help slow down or stop the growth of the cancer. Sotorasib is the first targeted agent approved for this specific mutation in patients who have previously received treatment.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is sotorasib safe for humans?
What makes the drug Sotorasib unique for treating solid cancers?
Sotorasib is unique because it is the first drug specifically targeting the KRAS G12C mutation, which is common in certain solid tumors like non-small cell lung cancer. It works by binding irreversibly to the mutated protein, blocking signals that promote cancer cell growth, and is taken orally, making it more convenient than some other treatments.12367
What data supports the effectiveness of the drug Sotorasib for solid cancers?
Sotorasib has shown promising results in treating non-small cell lung cancer (NSCLC) with KRAS G12C mutations, with a significant number of patients responding to the treatment and experiencing a median progression-free survival of almost 7 months. It has been approved for use in patients with this specific mutation who have already tried other treatments.12389
Who Is on the Research Team?
MD
Principal Investigator
Amgen
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced solid tumors that have a specific mutation called KRAS p.G12C. Participants must have their condition confirmed by certain lab tests. People with primary brain tumors, recent heart attacks, or issues that prevent taking oral meds can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Exploration
Participants receive sotorasib in combination with other therapies to determine the optimal dose
Dose Expansion
Participants continue to receive the determined dose to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Sotorasib
Sotorasib is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London